TARCEVA Drug Patent Profile
✉ Email this page to a colleague
When do Tarceva patents expire, and when can generic versions of Tarceva launch?
Tarceva is a drug marketed by Osi Pharms and is included in one NDA.
The generic ingredient in TARCEVA is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tarceva
A generic version of TARCEVA was approved as erlotinib hydrochloride by RISING on June 11th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TARCEVA?
- What are the global sales for TARCEVA?
- What is Average Wholesale Price for TARCEVA?
Summary for TARCEVA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 240 |
Clinical Trials: | 428 |
Patent Applications: | 873 |
Drug Prices: | Drug price information for TARCEVA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TARCEVA |
What excipients (inactive ingredients) are in TARCEVA? | TARCEVA excipients list |
DailyMed Link: | TARCEVA at DailyMed |
Recent Clinical Trials for TARCEVA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hala Fadda | Phase 1 |
Butler University | Phase 1 |
Indiana University | Phase 1 |
Pharmacology for TARCEVA
Drug Class | Kinase Inhibitor |
Mechanism of Action | Protein Kinase Inhibitors |
Paragraph IV (Patent) Challenges for TARCEVA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TARCEVA | Tablets | erlotinib hydrochloride | 25 mg | 021743 | 1 | 2008-11-18 |
US Patents and Regulatory Information for TARCEVA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-002 | Nov 18, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-003 | Nov 18, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TARCEVA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-003 | Nov 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-002 | Nov 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-003 | Nov 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TARCEVA
See the table below for patents covering TARCEVA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Malaysia | 117896 | QUINAZOLINE DERIVATIVES | ⤷ Sign Up |
Mexico | 9707453 | DERIVADOS DE QUINAZOLINA. (QUINAZOLINE DERIVATIVES.) | ⤷ Sign Up |
European Patent Office | 1233948 | POLYMORPHE STABLE DE CHLORHYDRATE DE N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE, ET METHODES DE PRODUCTION ET UTILISATIONS PHARMACEUTIQUES DUDIT POLYMORPHE (STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF) | ⤷ Sign Up |
Yugoslavia | 34202 | ⤷ Sign Up | |
Montenegro | P36308 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TARCEVA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0817775 | 300214 | Netherlands | ⤷ Sign Up | 300214, 20150606, EXPIRES: 20200320 |
0817775 | 5/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321 |
0817775 | C300214 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ERLOTINIB, DESGEWENST IN DE; REGISTRATION NO/DATE: 57266 01,..02,..03EU/1/05/311/001...003 20050321 |
0817775 | SPC001/2006 | Ireland | ⤷ Sign Up | SPC001/2006: 20070817, EXPIRES: 20200320 |
0817775 | 06C0010 | France | ⤷ Sign Up | PRODUCT NAME: ERLOTINIB HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 20050919; FIRST REGISTRATION: LI - 57266 20050321 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |